Skip to main content
SLN
NASDAQ Life Sciences

Controlling Shareholder Richard Griffiths Sells $87.7M in ADSs, Stake Falls to 7.97%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$14
Mkt Cap
$641.61M
52W Low
$4.19
52W High
$17.576
52W Position info
234% above low
Off High info
20% below high
Rel. Volume info
3.2× avg
Market data snapshot near publication time

SLN has more than doubled off its 52-week low of $4.19 on elevated volume (3.2× avg).

Summary

Controlling shareholder Richard Griffiths sold $87.7 million in ADSs, cutting his stake from 21.7% to 7.97% amid the company's $175 million offering.


Key Events · Ownership and Investor Activity · SLN

  • Controlling Shareholder Sells $87.7M

    Richard Griffiths sold 5,484,320 ADSs between August 10-12, 2026 for aggregate proceeds of $87.7 million.

  • Stake Falls to 7.97%

    Griffiths' ownership dropped from 21.7% to 7.97% of outstanding ordinary shares, reflecting both the sales and dilution from the $175 million offering.

  • Sales Coincide with Offering

    The sales occurred immediately after positive Phase 2 data for divesiran and concurrent with the company's upsized public offering priced at $13.50 per ADS.

  • Loss of Controlling Position

    Griffiths is no longer the controlling shareholder, a significant governance change for the company.


Analysis · SLN · Life Sciences

A significant governance shift unfolds as Richard Griffiths, the controlling shareholder, sells 5,484,320 ADSs for $87.7 million between August 10-12, 2026, reducing his stake from 21.7% to 7.97%. The sales come immediately after the company's positive Phase 2 data for divesiran and concurrent with the $175 million public offering priced at $13.50 per ADS. The stake reduction reflects both the open market sales and dilution from the offering. Griffiths' exit from a controlling position is a significant governance event, as he was the largest shareholder and a director.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLN was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $641.6M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLN - Latest Insights

SLN
Oct 19, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.76 info
Change: +$10.66 (+117%) info
Market Cap: $1.226B info
SLN
Oct 19, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $9.10
Real-time Price: $19.76 info
Change: +$10.66 (+117%) info
Market Cap: $1.226B info
SLN
Aug 14, 2026, 4:55 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.72
Real-time Price: $19.76 info
Change: +$6.03 (+44%) info
Market Cap: $1.226B info
SLN
Aug 13, 2026, 10:07 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $14.15
Real-time Price: $19.76 info
Change: +$5.60 (+40%) info
Market Cap: $1.226B info
SLN
Aug 12, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $19.76 info
Change: +$5.81 (+42%) info
Market Cap: $1.226B info